Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
USPIO Enhanced MRI in Secondary Progressive Multiple Sclerosis
NCT05357833Phase 1Completed
- Sponsor
- University of Utah
- Start
- Jun 2022
- Primary completion
- Sep 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ferumoxytol in secondary-progressive multiple sclerosis (SPMS), sponsored by University of Utah. Primary endpoint: Signal change on T1-weighted and 3D UTE MRI brain at 96 hours. Started Jun 2022; status: completed.
02
Drugs
ferumoxytol
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT05357833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357833.